



# > cantech letter



## Why you should be buying biotech stocks right now

FEBRUARY 10, 2016 BY EDEN RAHIMO COMMENTS

Share this: [Tweet](#) [+1](#) 3 [Like](#) 2



The Nasdaq Biotechnology Equal Weight Index.

2003) was earned by managing these volatile assets through four such epic monthly declines (Aug 98, Mar 00, Nov 00 and Mar 01). It was not fun, but it always represented opportunity.

We have now seen the negative side of volatility in spades. But volatility works in both directions. Over the same 27 year period, there have been 15 months that appreciated over 20%, a ratio of 2:1.

As difficult as it is to weather such storms, in all prior six such monthly declines, the sector was flat or positive one quarter later.

January witnessed a rare and dreadful month where biotech indices fell over -20%, and most biotech stocks fell much more. In fact, January was the seventh monthly decline exceeding -20% in past 27 years.

Having the wounds to prove I have managed this wild stallion of a sector through every environment, nevertheless, my long term Healthcare Fund 5-year 5-star performance (1998-



## > cantech newswire

- Optiv Further Strengthens Commitment to Helping Organizations Proactively Solve Cyber Security Problems
- 2016 GSMA Mobile World Congress Surpasses Record 100,000 Visitors
- Intermountain Healthcare Enters into Agreement to Use Avastor's Clinical Variation Management Software to Accelerate Insights
- Sight Machine Selected by Martineira Manchester Division for Digital Transformation of Manufacturing
- Perk.com Inc. Announces Partnership with Celltick to Power Rewards across its Millions of Installations Globally
- Manipal Hospitals is the First in India to Adopt Masimo Patient SafetyNet
- GSMA Announces Winners of the 2016 Glomo Awards
- CUP and Visa Sign MOU to Collaborate on Payments Security, Innovation and Financial Inclusion

Submit news here  
More news...

### SEARCH THE SITE



### FREE E-NEWSLETTER

Cantech Letter's free e-newsletter. Enter your email in the box below and never miss a hot tech stock again. We don't spam and you can unsubscribe anytime.

E-mail Address \*

Submit


### 3-MONTH RETURNS AFTER Largest Monthly Declines

DATE	DECLINE	RETURN
Apr-1992	-20.2%	12.1%
Feb-1993	-20.3%	-0.1%
Aug-1998	-24.3%	56.6%
Mar-2000	-28.7%	28.8%
Nov-2000	-20.9%	2.0%
Mar-2001	-20.6%	30.1%
Jan-2016	-24.1%	?

Source: Bloomberg Data, Next Edge Capital

## ANYTHING BUT NORMAL

As can be seen from the distribution of monthly returns for Biotech vs the S&P, Biotech is characterized by 'Fat Tails' in abundance vs the normal distribution for the S&P. Such dispersion of returns is the footprint of Biotech that must overcome binary events and high barriers-to-entry on the path to enormous profit growth. In fact, 7% of months experience a + or - 20% return vs 0 for the S&P, while an eye-opening 24% of months experience a + or -10% return vs 2% for the S&P.



Source: Bloomberg Data, Next Edge Capital


## GROWTH IN A SLOW-GROWTH ECONOMY

The investing world flounders in search of growth that is not economically sensitive, fleeing to the ever crowded high-ground in mega-cap Technology titans. In the meantime, Biotech continues to innovate and advance breakthroughs at an accelerating rate.

During the five year period 2006-to-2010, an average of 22 New Molecular Entities (NME) were approved each year. As the decade turned, and the biotech bull began, that average rose to 32 approvals per year over 2011 to 2013.

In the past two years, it has again accelerated to a record 45 during 2015. Given what we know about the pipeline of innovative products in late stage development, that rate of product approvals is likely to continue.

### CDER New Molecular Entity (NME) and New Biologic License Application (BLA) Filings and Approvals



Source: US Food & Drug Administration (FDA)

### CALLING ALL CONTRARIANS

While investors seldom have the emotional resolve to step-up and Buy when an asset class is declining with impunity, that is when Technical indicators can shine a light on appropriate points to attempt. In particular, a) Oversold Indicators b) Sentiment Indicators c) Valuation indicators d) Long term trend (Secular Bull or Secular Bear?)

The percent of 150 Nasdaq Biotech index component stocks above their 200-day moving averages has decline to the lowest reading at 13% in 7 years since the bear market depression low in March 2009 when a reading of 8% was registered.


Furthermore, sentiment toward the sector has declined to the most bearish of all asset classes, making positive surprises that much more impactful. With readings so rare it confirms the proverbial elastic band is indeed stretched.



Source: Sentimentrader.com

### Sectors Ranked By Lowest-Highest Optimism


### Sectors Ranked By Lowest - Highest Optimism Index



Source: Sentimentrader.com

Finally, the percent of Nasdaq biotech index stocks trading for 'Zero Pipeline' or negative enterprise value is approaching 20% - the 3rd highest reading in 25 years. That was eclipsed only by the 22% and 27% readings registered at the depths of the multiyear bear markets that troughed in 2002 and 2009. Collectively, these oversold indicators point to a healthy Risk / Reward set up in a sector that is in a long term secular bull market.

### Un-Profitable U.S. Biotech \$0 - 2.5Bn Market Cap



Source: Mark Schoenebaum, ISI Evercore

Disclaimer: Cantech Letter is an online magazine focusing on Canadian listed technology stocks on the TSX & TSX-V Exchanges (the "Service"). Cantech Letter is a publication of Cantech Media.

Cantech Media does not represent, warranty, or endorse the accuracy, reliability, completeness or timeliness of any of the information, content, views, opinions, or advertisements contained within or distributed by the Service.

THE SERVICE DOES NOT CONSTITUTE INVESTMENT ADVICE OR ADVOCATE THE PURCHASE OR SALE OF ANY OF THE SECURITIES MENTIONED AS PART OF THE SERVICE.

None of the information contained in the Service constitutes an offer to sell or a solicitation to buy any security of any kind of any issuer.

By using the Service you acknowledge that Cantech Media will not be liable for any direct, indirect, incidental, punitive, or consequential damages of any kind whatsoever which may result from the use of the

---

## Related Cantech Letter Posts

[Bioniche Life Sciences rallies around milestone payments](#)



[Prometic Life Sciences continues its meteoric rise](#)



[Prometic Life Sciences offers compelling risk/reward scenario, says Paradigm](#)

Follow [@cantechletter](#)

for all the latest on Canadian Technology

Get the latest opinions from Canadian Tech Experts With Our Weekly Newsletter



### About Eden Rahim

Eden's approach represents a progression in Investment solutions, applying options to source Income and returns through strategies not easily accessible to investors, while protecting their capital with hedges designed over his career.

Eden's experience includes two decades of Portfolio and Hedge Fund Money Management, Options Strategist, Derivatives & Biotech Analyst and Portfolio Manager. He has managed and traded an options book spanning 250+ securities globally and 4 commodities, with open interest of 500,000 contracts in addition to 14 Covered Call ETFs (over \$0.5 Billion AUM) in Canada, US & Australia employing his dynamic options writing discipline at Horizons Exchange Traded Funds.

Eden possesses a Top Quartile 5-year, 5-Star growth fund Portfolio Manager track record on over \$1 billion in assets across 4 mandates at RBC Global Asset Management. In addition, Eden has delivered a +26% compounded annual return across a Biotechnology mandate between 1995-2003. He also has extensive institutional hedging experience through major crises, and the structuring of Notes to create specific payoff profiles.



Be the first to comment.